Section snippets

Tranexamic acid not recommended for liver cancer surgery

Tranexamic acid does not reduce bleeding and increases major complications in liver cancer surgery, according to new findings from the HeLiX trial. Paul Karanicolas and colleagues randomly assigned patients undergoing liver resection for cancer to receive either tranexamic acid (n=619) or matching placebo (n=626) beginning at induction of anaesthesia. The primary outcome—receipt of a red blood cell transfusion within 7 days of surgery—occurred in 101 (16%) patients in the tranexamic acid group

Oral microbiome therapeutic for recurrent C difficile

CP101, an oral microbiome therapeutic, restores microbiome diversity and offers a safe effective treatment option for recurrent C difficile infections, according to a phase 2 trial. Jessica Allegretti and colleagues randomly assigned participants with recurrent C difficile to receive a single oral dose of either CP101 (n=102) or placebo (n=96) after standard-of-care antibiotics. At week 8, a significantly higher proportion of participants in the CP101 group achieved had not had C difficile

Liver transplantation for inoperative colorectal liver metastases

Long-term survival is possible after liver transplant for colorectal liver metastases, according to the TransMet trial. René Adam and colleagues randomly assigned patients with permanently unresectable colorectal liver metastases to receive liver transplantation plus chemotherapy (n=47) or chemotherapy alone (n=47). The per-protocol population of patients who received the assigned treatment included 36 patients in liver transplantation plus chemotherapy group and 38 in the chemotherapy alone

Palliative radiotherapy for hepatic cancer

Low-dose liver radiotherapy improves pain in patients receiving palliative care for hepatic cancer, a phase 3 trial suggests. Laura Dawson and colleagues randomly assigned patients with hepatocellular carcinoma or liver metastases, and a pain score of at least 4 out of 10 “at its worst in the past 24 hours” on the Brief Pain Inventory, to receive a single fraction of radiotherapy (8 Gy) plus best supportive care (n=33) or best supportive care alone (n=33). At median follow-up of 3·2 months,

Tulisokibart for ulcerative colitis

Tulisokibart—a TNF–like cytokine 1A (TL1A) monoclonal antibody—shows promise in patients with moderately to severely active ulcerative colitis, according to the ARTEMIS-UC phase 2 trial. Bruce Sands and colleagues enrolled patients with glucocorticoid dependence or failure of conventional or advanced therapies for ulcerative colitis into two cohorts. Cohort 1 included patients regardless of their status on a genetic-based diagnostic test designed to identify those with an increased likelihood

中文翻译：

---

 研究简介

 部分片段

氨甲环酸不推荐用于肝癌手术

根据 HeLiX 试验的新发现，氨甲环酸不会减少出血并增加肝癌手术的主要并发症。Paul Karanicolas 及其同事将接受肝切除术的癌症患者随机分配至麻醉诱导开始接受氨甲环酸 （n=619） 或匹配的安慰剂 （n=626）。主要结局 — 手术后 7 天内接受红细胞输注 — 发生在氨甲环酸组的 101 例 （16%） 患者中

口服微生物组治疗复发性艰难梭菌

根据一项 2 期试验，CP101 是一种口服微生物组治疗药物，可恢复微生物组的多样性，并为复发性艰难梭菌感染提供安全有效的治疗选择。Jessica Allegretti 及其同事将复发性艰难梭菌参与者随机分配在标准护理抗生素后接受单次口服剂量的 CP101 （n=102） 或安慰剂 （n=96）。在第 8 周时，CP101 组中未患有艰难梭菌的参与者比例显著更高

肝移植治疗非手术性结直肠肝转移

根据 TransMet 试验，结直肠肝转移的肝移植后有可能长期生存。René Adam 及其同事将永久不可切除的结直肠肝转移患者随机分配接受肝移植联合化疗 （n=47） 或单独化疗 （n=47）。接受指定治疗的患者的方案人群包括 36 名肝移植加化疗组患者和 38 名单独化疗患者

肝癌的姑息性放疗

一项 3 期试验表明，低剂量肝脏放疗可改善接受肝癌姑息治疗的患者的疼痛。Laura Dawson 及其同事将肝细胞癌或肝转移患者随机分配，并且在简要疼痛量表上“过去 24 小时内最严重”的疼痛评分至少为 4 分（满分 10 分），接受单部分放疗 （8 Gy） 加上最佳支持治疗 （n=33） 或单独使用最佳支持治疗 （n=33）。中位随访 3·2 个月时，

Tulisokibart 治疗溃疡性结肠炎

根据 ARTEMIS-UC 2 期试验，Tulisokibart 是一种 TNF 样细胞因子 1A （TL1A） 单克隆抗体，在中度至重度活动性溃疡性结肠炎患者中显示出前景。Bruce Sands 及其同事将糖皮质激素依赖或溃疡性结肠炎常规或高级疗法失败的患者纳入两个队列。队列 1 包括患者，无论他们的状态如何，都接受了一项基于遗传的诊断测试，旨在识别那些可能性增加的人